1. Home
  2. BVS vs GERN Comparison

BVS vs GERN Comparison

Compare BVS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$14.38

Market Cap

783.2M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.52

Market Cap

911.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVS
GERN
Founded
2011
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.2M
911.0M
IPO Year
2016
1996

Fundamental Metrics

Financial Performance
Metric
BVS
GERN
Price
$14.38
$1.52
Analyst Decision
Strong Buy
Hold
Analyst Count
3
3
Target Price
$14.00
$2.17
AVG Volume (30 Days)
810.2K
10.8M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
163.46
51.85
EPS
0.52
N/A
Revenue
$568,087,000.00
$1,065,000.00
Revenue This Year
$7.52
$26.91
Revenue Next Year
$7.06
$43.75
P/E Ratio
$27.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.26
$1.04
52 Week High
$15.89
$2.01

Technical Indicators

Market Signals
Indicator
BVS
GERN
Relative Strength Index (RSI) 61.47 52.18
Support Level $7.29 $1.42
Resistance Level $15.89 $1.68
Average True Range (ATR) 0.78 0.10
MACD -0.06 0.00
Stochastic Oscillator 51.67 58.82

Price Performance

Historical Comparison
BVS
GERN

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: